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Abstract
Background: Preterm infants requiring assisted ventilation are at significant risk of both pulmonary and cerebral injury. 
Inhaled Nitric Oxide, an effective therapy for pulmonary hypertension and hypoxic respiratory failure in the full term 
infant, has also been studied in preterm infants. The most recent Cochrane review of preterm infants includes 11 
studies and 3,370 participants. The results show a statistically significant reduction in the combined outcome of death 
or chronic lung disease (CLD) in two studies with routine use of iNO in intubated preterm infants. However, uncertainty 
remains as a larger study (Kinsella 2006) showed no significant benefit for iNO for this combined outcome. Also, trials 
that included very ill infants do not demonstrate significant benefit. One trial of iNO treatment at a later postnatal age 
reported a decrease in the incidence of CLD. The aim of this individual patient meta-analysis is to confirm or refute 
these potentially conflicting results and to determine the extent to which patient or treatment characteristics may 
explain the results and/or may predict benefit from inhaled Nitric Oxide in preterm infants.
Methods/Design: The Meta-Analysis of Preterm Patients on inhaled Nitric Oxide (MAPPiNO) Collaboration will 
perform an individual patient data meta-analysis to answer these important clinical questions. Studies will be included 
if preterm infants receiving assisted ventilation are randomized to receive inhaled Nitric Oxide or to a control group. 
The individual patient data provided by the Collaborators will be analyzed on an intention-to-treat basis where 
possible. Binary outcomes will be analyzed using log-binomial regression models and continuous outcomes will be 
analyzed using linear fixed effects models. Adjustments for trial differences will be made by including the trial variable 
in the model specification.
Discussion: Thirteen (13) trials, with a total of 3567 infants are eligible for inclusion in the MAPPiNO systematic review. 
To date 11 trials (n = 3298, 92% of available patients) have agreed to participate. Funding was successfully granted from 
Ikaria Inc as an unrestricted grant. A collaborative group was formed in 2006 with data collection commencing in 2007. 
It is anticipated that data analysis will commence in late 2009 with results being publicly available in 2010.
Background
Approximately 8-13% of infants are born prematurely
across developed countries. Preterm delivery accounts
for 75-80% of all neonatal morbidity and mortality [1,2].
Although survival rates have markedly improved in
recent decades, premature infants requiring assisted ven-
tilation are still at significant risk of both pulmonary and
cerebral injury.
An estimated 75% of the infants with a birth weight less
than 1000 grams develop respiratory distress syndrome
(RDS), and nearly 30% are still oxygen dependent at a
postmenstrual age of 36 weeks [3]. The commonest defi-
nition of chronic lung disease (CLD) is oxygen depen-
dency or respiratory support at 36 weeks postmenstrual
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Page 2 of 10age. Infants with severe CLD remain at high risk for pul-
monary morbidity and mortality during the first two
years of life [4]. In addition, long-term neurodevelopmen-
tal impairments associated with cerebral palsy, mental
retardation, sensorineural hearing loss, and visual impair-
ment are frequently observed in infants with CLD [5,6].
The incidence rate of these neurodevelopmental impair-
ments increases with decreasing birth weight. Neonates
with birth weights of 1501 to 2500 grams have an 8% inci-
dence, compared with a 25% rate in infants born weighing
less than 1000 g [7].
Nitric Oxide (NO) relaxes vascular smooth muscle by
activating guanyl cyclase and leading to the production of
cyclic GMP [8]. The first experimental study in immature
lambs reported that exogenous inhaled NO (iNO) selec-
tively increased pulmonary blood flow and reduced pul-
monary artery pressure [9]. Studies in adults also show
that iNO improves ventilation/perfusion mismatch by
selective pulmonary vasodilation [10,11]. A meta-analysis
showed iNO improved oxygenation in approximately 50%
of full term or near term infants with pulmonary hyper-
tension and hypoxic respiratory failure. There was a sig-
nificant reduction in the incidence of death or
requirement for extracorporeal membrane oxygenation
(ECMO). However, the authors emphasized that results
of iNO in term infants cannot be extrapolated to the pre-
mature infants because of different pathophysiology, dif-
ferent inclusion criteria, and different outcomes assessed
[8]. Although initially investigated for its pulmonary
vasodilating effect, it has become clear that the potential
pulmonary effects of iNO are multiple and complex.
There are pro-oxidant and anti-oxidant effects [12] and in
experimental animal models of neonatal chronic lung dis-
ease, pulmonary structure and function are protected by
iNO [13], suggesting that there are direct effects which
could potentially reduce chronic lung disease.
Several randomized controlled trials have been con-
ducted in preterm infants to determine whether iNO
reduces the rates of death and/or chronic lung disease
[14-26]. The results of these studies appear contradictory.
Some studies have shown a reduction in lung injury, one
has shown a reduction in cerebral injury, and several oth-
ers have shown no effect. The different patient character-
istics and different trial characteristics within these trials
may explain this difference.
Summary of aggregate data systematic review in 2007
The most recent Cochrane review includes 11 studies and
3,370 participants [27]. These studies differ not only in
their design and intervention, but in the eligible patient
populations. For example, Schreiber 2003 and Kinsella
2006 studied the routine use of inhaled NO in all intu-
bated preterm infants who had a relatively low oxygen
requirement and severity of illness at intubation [22,20].
The studies by Van Meurs et al [26] and the INNOVO
study group from the UK [18], in contrast, only enrolled
patients with severe hypoxic respiratory failure and as a
result had extremely high incidences of the combined
outcome of death or CLD. The entry criteria also differed
with most studies enrolling infants in the first 48 hours,
but Ballard et al [14,15] enrolled infants between 7 and 21
days who were at high risk of developing CLD. Hence, the
review authors divided these trials into three categories
based on different entry criteria: entry in the first three
days of life according to oxygenation criteria, routine use
in intubated preterm babies and later enrolment based on
an increased risk of CLD. The results showed there was a
marginally significant reduction in death or CLD at 36
weeks with a relative risk of 0.91 (95% CI 0.84-0.99) in
studies with routine use of iNO in intubated preterm
infants. However, trials of early treatment of infants
based on oxygenation criteria or of later enrolment based
on the risk of CLD did not demonstrate significant bene-
fit of iNO for the primary end point of death or CLD at 36
weeks, when analyzed according to standard aggregate
data meta-analytic techniques. Almost all information
from late enrolled babies is derived from a single large
study (Ballard et al) which reported a significant reduc-
tion in the outcome of death or CLD [14,15]. These data
were analyzed using a new method (multiple outputa-
tion) to account for potential confounding effects of
enrolling infants from multiple gestations, of whom only
the first eligible infant was randomized. One way in
which to confirm or refute these results and to determine
whether certain patient or treatment characteristics may
predict benefit from inhaled Nitric Oxide in premature
infants is by means of an individual patient data meta-
analysis.
The advantages of an individual patient data meta-anal-
ysis over a meta-analysis based on aggregate data are as
follows:
• It is possible to ensure uniformity in defining patient
characteristics and outcome measures.
• Such analysis can assess the relationship between
patient-level characteristics and treatment effect,
resulting in a differentiation of the treatment effect
according to risk profiles.
• A more accurate assessment of how trial character-
istics may affect response is feasible.
• Information on long-term outcome can be updated.
• It is possible to develop predictive models using
multivariate regression analyses.
Objectives
1. To determine whether inhaled Nitric Oxide in pre-
term infants receiving assisted ventilation improves
survival without morbidity, specifically without CLD
or major neurological injury.
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Oxide differ according to the risk profile of the patient
in terms of gestational age at birth, severity of illness,
antenatal steroid use, postnatal age at the time of ran-
domization, ventilation mode at randomization,
administration of exogenous surfactant, inhaled
Nitric Oxide dosage and duration of administration.
Methods
Inclusion criteria for studies
Study design: Studies will be included if they are random-
ized controlled trials.
Participants: Preterm infants (less than 37 weeks gesta-
tion) receiving assisted ventilation. Intervention: Inhaled
Nitric Oxide compared to control.
Search strategy
The standard search strategy of the Cochrane Neonatal
Review Group will be used to identify potentially eligible
studies. This involves extensive searching of bibliographic
databases such as MEDLINE, EMBASE.com, The
Cochrane Controlled Trials Register and Healthstar from
1985 to 2009. The terms "Nitric Oxide" and "newborn"
will be used and the search limited to clinical trial. The
abstracts of the Pediatric Academic Societies will also be
searched from 2000 to 2009. In addition, all members of
the Collaborative Group will be asked to notify the group
of any unpublished trials of which they are aware. See
Table 1 for the citations of known eligible studies at Octo-
ber 2009 and Table 2 for a description of these studies.
Data management
De-identified individual patient data provided by the Col-
laborators (see Additional file 1 for the suggested coding
sheet and Additional file 2 for the data provision form)
will be recoded as required and stored in an electronic
database at the Data Coordination Centre. Electronic
data will be located on a secure password-protected net-
work server. Copies of hardcopy data will be stored in
locked filing cabinets until converted into electronic for-
mat, and will then be securely destroyed. Only authorized
personnel will have access to this data.
The data will be checked with respect to range, internal
consistency, consistency with published reports and
missing items. Trial details such as randomization, meth-
ods and intervention details will be crosschecked against
published reports, trial protocols and data collection
sheets. Inconsistencies or missing data will be discussed
with the individual trialists, and attempts will be made to
resolve any discrepancies by consensus. Each trial will be
analyzed individually and the resulting analyses and trial
data will be sent to the trialists' for verification.
Table 1: MAPPiNO Collaboration: citations for eligible trials 
as at October 2009
Trial 
identifier
Main citation
Ballard 2006 Ballard RA, Truog WE, Cnaan A, et al. Inhaled 
Nitric Oxide in preterm infants undergoing 
mechanical ventilation. New England Journal 
of Medicine 2006; 355(4):343-53.
Dani 2006 Dani C, Bertini G, Pezzati M, et al. Inhaled 
Nitric Oxide in very preterm infants with 
severe respiratory distress syndrome. Acta 
Pediatrica 2006; 95: 1116-1123.
Hascoet 2005 Hascoet JM, Fresson J, Claris O, et al. The 
safety and efficacy of Nitric Oxide therapy in 
premature infants. Journal of Pediatrics 2005; 
146 (3):318-23.
INNOVO 2005 INNOVO. Neonatal ventilation with inhaled 
Nitric Oxide versus ventilatory support 
without inhaled Nitric Oxide for preterm 
infants with severe respiratory failure: the 
INNOVO multicentre randomized controlled 
trial. Pediatrics 2005; 115 (4):926-36.
Kinsella 1999 Kinsella JP. Inhaled Nitric Oxide in premature 
neonates with severe hypoxaemic 
respiratory failure: a randomised controlled 
trial. Lancet 1999; 354(9184):1061.
Kinsella 2006 Kinsella JP, Cutter GR, Walsh WF, et al. Early 
inhaled Nitric Oxide therapy in premature 
newborns with respiratory failure. New 
England Journal of Medicine 2006; 
355(4):354-64.
Mercier 1999 Mercier JC, Thebaud B, Onody P. Early 
compared with delayed inhaled Nitric Oxide 
in moderately hypoxaemic neonates with 
respiratory failure: a randomised controlled 
trial. Lancet 1999; 354(9184):1066.
Schreiber 
2003
Schreiber MD, Gin-Mestan K, Marks JD, et al. 
Inhaled Nitric Oxide in Premature Infants 
with the Respiratory Distress Syndrome. New 
England Journal of Medicine 2003; 
349(22):2099-107.
Mestan KKL, Marks JD, Hecox K, et al. 
Neurodevelopmental Outcomes of 
Premature Infants Treated with Inhaled 
Nitric Oxide. New England Journal of 
Medicine 2005; 353(1):23-32.
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Trial-level information: obtained from the trial protocol
and/or the trialists
1. Dates the trial opened and closed to accrual
2. Number of patients randomized
3. Informed consent procedures
4. Methods of random allocation
5. Stratification factors used
6. Methods of allocation of concealment
7. Blinding of outcome assessment
8. Details of the intervention in the experimental arm
• Inhaled Nitric Oxide concentration
• Durations allowed
• Protocol for weaning
• Target oxygen saturation range
• Target blood gas range
9. Details of the intervention in the control arm
• Target oxygen saturation range
• Target blood gas value range
10. Criteria for permitted crossover from the
assigned treatment
11. Criteria for failure of assigned treatment
12. Details of surfactant replacement therapy, if
determined by the protocol
13. Criteria for postnatal treatment with systemic
corticosteroids
Patient-level information: characteristics at study entry
1. Unique identification coded for anonymity
2. Time or postnatal age at intubation
3. Time or postnatal age at randomization
4. Gestational age at birth
5. Birth weight
6. Antenatal corticosteroid therapy, complete (>24
hours) or not
7. Sex
8. Race
9. Inborn/outborn status
10. Type of respiratory support (endotracheal tube -
conventional or high frequency, nasal CPAP, other)
11. Ventilator rate at time of randomization
12. Components of a respiratory severity score at
time of randomization (PIP, MAP and FiO2)
13. PaCO2 at time of randomization
14. PaO2 or oxygen saturation at time of randomiza-
tion
15. Use of surfactant replacement therapy
16. Type of surfactant used (natural or synthetic)
17. Postnatal age at first dose of surfactant
18. Prophylactic indomethacin
19. PDA
20. Postnatal treatment with systemic corticosteroids
21. Worst pre-randomization cranial ultrasound
result
Patient-level information: data on actual study inter-
vention
1. Study gas assigned
2. Highest and starting dosage received
3. Duration of therapy
4. Any re-treatment after study period
5. Other drugs in same pathway
6. Change in ventilation mode during therapy (CMV
to HFV or vice versa)
7. Failure of assigned treatment
8. Need for treatment crossover during study period
Patient-level information: data on neonatal outcome
1. Mortality and age at death
2. Duration of mechanical ventilation
3. Duration of oxygen therapy
4. Duration of any respiratory support (mechanical
ventilation, CPAP or oxygen)
Srisuparp 
2002
Srisuparp P, Heitschmidt M, Schreiber MD. 
Inhaled Nitric Oxide therapy in premature 
infants with mild to moderate respiratory 
distress syndrome. J Med Assoc Thai 2002; 
85(Suppl 2): S469-S478.
Su 2008 Su PH, Chen JY. Inhaled Nitric Oxide in the 
management of preterm infants with severe 
respiratory failure. Journal of Perinatology 
2008; 28: 112-116.
Subhedar 
1997
Subhedar NV, Ryan SW, Shaw NJ. Open 
randomised controlled trial of inhaled Nitric 
Oxide and early dexamethasone in high risk 
preterm infants. Arch Dis Child Fetal Neonatal 
Ed 1997; 77(3): F185-F190.
Subhedar NV, Shaw NJ. Changes in 
oxygenation and pulmonary 
haemodynamics in preterm infants treated 
with inhaled Nitric Oxide. Arch Dis Child Fetal 
Neonatal Ed 1997; 77(3):F191-F197.
Van Meurs 
2005
Van Meurs KP, Wright LL, Ehrenkranz RA, et 
al. Inhaled Nitric Oxide for Premature Infants 
with Severe Respiratory Failure. New England 
Journal of Medicine 2005; 353(1):13-22.
EUNO 2008 
(completed 
RCT awaiting 
publication)
JC Mercier, H. Hummler, X Durrmeyer, et al. 
The effects of inhaled Nitric Oxide on the 
development of bronchopulmonary 
dysplasia in preterm infants: the 'EUNO' 
multicentre randomised clinical trial. 
Abstract: European Academy of Pediatrics, 
Nice, France, October 25, 2008.
Table 1: MAPPiNO Collaboration: citations for eligible trials 
as at October 2009 (Continued)
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Page 5 of 105. Gross pulmonary air leak (pneumothorax or other
gross air leak including pneumomediastinum, pneu-
mopericardium or pneumoperitoneum)
6. Pulmonary interstitial emphysema
7. Pulmonary hemorrhage
8. Worst post-randomization cranial ultrasound
result (including acute periventricular hemorrhage
such as subependymal, intraventricular or intracere-
bral)
9. Ventricular dilatation at any stage
10. Cystic periventricular leukomalacia
11. Worst stage of retinopathy of prematurity (ROP)
12. Threshold ROP
13. Surgical or laser therapy for ROP
14. Duration of hospital stay
15. Home oxygen therapy
Planned analyses
Binary outcomes will be analyzed using log-binomial
regression models adjusting for trial differences by
including the trial variable in the model specification.
Exponentiating the parameter estimate for treatment
from a log-binomial regression model produces a relative
risk for treatment.
Outcomes between siblings from multiple births are
highly correlated and must be accounted for in the analy-
sis. There are two main methods of adjusting for such
'clustered' data which will be utilized in this study. The
primary method will be the multiple outputation
approach. This method involves randomly selecting one
patient from each sibling cluster and running the analysis
on this set of independent data to obtain an estimate of
the effect  and an estimate of its variance . This
process is then repeated N times. The average of the esti-
mated  's from each iteration  is used as the esti-
mate of the overall effect and an estimate of the variance
is given by the average of the variances  minus the
variance of the effect estimates [28]. This
method involves no additional assumption about correla-
tions between siblings and therefore avoids problems of
numerical instability when fitting the models.
As a sensitivity analysis, additional methods of
accounting for correlations within the data will be used
on the primary outcomes. For example generalized esti-
mating equations (GEE) may be used to analyse the two
main endpoints of interest (death or CLD and neurologi-
cal injury). The GEE model is a repeated measures model
for binary outcomes which accounts for the correlation
between siblings.
Continuous normally distributed endpoints will be ana-
lyzed using a linear fixed effects model. Additionally the
treatment by trial interaction will be assessed to investi-
gate possible heterogeneity of treatment effects [29]. The
overall estimated mean and standard deviation within
each treatment group will be presented along with the
mean difference in treatment effect and its 95% confi-
dence interval with p value. If the data do not meet the
assumptions for the model then transformations or alter-
native models will be investigated.
The MAPPiNO Collaboration aims to collect all the
available worldwide individual patient data for preterm
infants randomized in clinical trials assessing the effect of
inhaled Nitric Oxide. Currently there is a commitment to
provide data from 3298 infants in 11 trials (92% of world-
wide data). A sample size of this magnitude would have at
least 89% power to detect relative changes of 10% in the
risk of death or chronic lung disease (main outcome) for
the treated group across a range of plausible baseline
event rates (55-75%) with a two sided α = 5% and 1:1 ratio
for number treated to control.
A summary of the planned analyses is listed below. A
detailed analysis plan is outlined in a separate document
and available upon request.
Outcomes to be analyzed
The main analyses comparing the effect of inhaled Nitric
Oxide to standard therapy will be undertaken for the out-
comes listed below. The planned subgroups and sensitiv-
ity analyses will be restricted to the main outcomes.
a. Primary outcomes
• Death or chronic lung disease (CLD) using the best
available definition (alive and oxygen dependent at 36
weeks postmenstrual age (PMA) if calculable, other-
wise trialists' own definition)
• Severe adverse neurological event after randomiza-
tion (intracranial hemorrhage (IVH) grade III or IV,
or cystic periventricular leukomalacia (PVL) or other
pathologies such as periventricular echodensity,
periventricular cysts, ventriculomegaly or hydroceph-
alus)
b. Secondary outcomes
• Death at any time, by 36 weeks PMA and at dis-
charge
• Severe IVH (grade III or IV) with and without
adjustment for baseline IVH severity
• Survivors without CLD at 36 weeks PMA
• Severe adverse neurological event (IVH grade III or
IV, or PVL or other pathologies such as periventricu-
lar echodensity, periventricular cysts, ventriculomeg-
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Study Participants Intervention Primary outcome
Ballard 2006 582 infants <1250 g and <32 wks on 
assisted ventilation at 7-21 days (or, if 
<800 g, on CPAP)
Inhaled NO at 20 ppm initial dose for 48 to 96 hours, 
then dose subsequently decreased to 10, 5, and 2 
ppm at weekly intervals, with a minimum treatment 
duration of 24 days
Survival without BPD at 36 wks 
postmenstrual age
Dani 2006 40 infants <30 wks ventilated with 
severe RDS: FiO2 >0.5 and arterial-
alveolar oxygen ratio < 0.15 despite 
surfactant treatment
Inhaled NO at 10 ppm for 4 hours followed by 6 ppm. 
Weaning (decrease by 2 ppm every 3 hrs) started at 
72 hrs or when the infant was extubated or when the 
FiO2 <0.3 with a mean airway pressure <8 cmH2O
Death or BPD (oxygen 
requirement at 36 weeks 
postconceptional age) in 
survivors
Hascoet 2005 860 infants <32 wk enrolled at birth; n = 
145 infants were eligible for study gas as 
had hypoxic respiratory failure (defined 
as need for mechanical ventilation, 
FiO2>0.40 and arterio-alveolar O2 ratio 
<0.22) at 6-48 hrs age
Inhaled NO was administered starting at 5 ppm, 
with adjustments allowed depending on 
response up to a maximum of 10 ppm.
Subjects were allowed to receive (unblinded) iNO 
in either group if they developed refractory 
hypoxemia.
Intact survival at 28 days 
(defined as alive without need 
for oxygen supplementation or 
IVH >grade 1 or refractory 
hypoxaemia (need for 100% 
oxygen with PaO2<50 mmHg) 
and PCO2 <50 mmHg)
INNOVO 2005 108 preterm infants (<34 wks) less than 
28 days of age with severe respiratory 
failure requiring ventilator support and 
have had surfactant when appropriate
Inhaled NO usually at 5 ppm, up to 40 ppm based 
on response criteria (satisfactory response: 
increase in PaO2 >22.5 mmHg after 15 minutes 
iNO)
1) Death or severe disability at 1 
year corrected age; and
2) Death before discharge or 
continued oxygen need at 36 
wks pma and/or at expected 
date of delivery
Kinsella 1999 80 preterm infants (</= 34 weeks) aged 
7 days or less, with a/A ratio <0.1 on two 
sequential arterial blood measurements 
despite mechanical ventilation and 
surfactant treatment
Inhaled NO at 5 ppm for 7 days after which 
periods of no study gas were tried; threshold 
criteria for gas re-start was an increase of >/=15% 
in OI; maximum treatment duration was 14 days
Survival to discharge
Kinsella 2006 793 preterm infants < 34 wks, with 
respiratory failure needing assisted 
ventilation in first 48 hours of life
Inhaled NO at 5 ppm for 21 days or until 
extubation
Death or BPD (need for 
supplemental oxygen or 
mechanical ventilation at 36 wks 
pma and abnormal CXR)
Schreiber 
2003
207 infants < 34 wks and < 2000 g birth 
weight, < 72 hours of age, and 
intubated/ventilated for RDS, having 
had exogenous surfactant
Inhaled NO starting at 10 ppm for 12-24 hrs, then 
5 ppm for 6 days, then weaned by 1 ppm every 6 
hrs if PaO2 did not decrease by more than 15% 
until extubation; 2 × 2 factorial trial of iNO vs 
control gas and HFOV vs CMV
Death or CLD (supplemental 
oxygen and CXR showing 
persistent parenchymal lung 
disease at 36 weeks pma) 
among surviving infants
Srisuparp 
2002
34 infants < 2000 g, ventilated after 
surfactant with an arterial catheter and 
less than 72 hours of age + satisfying 
severity of illness criterion: OI >4 if 
birthweight<1000 g; >6 if 1001-1250 g; 
>8 if 1251-1500 g; >10 if 1501-1750 g; 
and >12 if 1751-2000 g birthweight
Inhaled NO at 20 ppm for 6-12 hrs, then reduced 
to 10 ppm, and weaned to 5 ppm in the next 12 
hrs; weaning tolerated if PaO2did not decrease by 
more than 15%; once 5 ppm achieved, weaning 
was attempted at 1 ppm a time as tolerated until 
gas discontinued; maximum duration allowed 
was 7 days
Severe intraventricular 
hemorrhage (grade 3 or 4)
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Page 7 of 10aly or hydrocephalus) with and without adjustment
for baseline status
• Postnatal steroid use
• Gross pulmonary air leak (at least one of the follow-
ing: pneumothorax, pneumomediastinum, pneumo-
peritoneum or pneumopericardium)
• Pulmonary hemorrhage
• Failure of assigned treatment
• Duration of oxygen therapy
• Duration of hospital stay
• Home oxygen therapy
• Severe retinopathy of prematurity (ROP stage >=3;
surgical or laser therapy for ROP)
• Postmenstrual age when ETT ceased
• Postmenstrual age when respiratory support ceased
• Postmenstrual age when discharge from hospital
c. Additional outcome
• In addition, CLD at 36 and 28 weeks postnatal age,
CLD as classified by the trialist and CLD classified
using the best available definition (alive, oxygen
dependent at 36 weeks or trialists' own definition) will
be assessed. However it is noted that since these out-
comes can only be assessed for babies who survive to
these time points, these do not constitute ITT analy-
ses nor are they randomized comparisons.
Planned subgroup analyses
One of the strengths of individual patient data meta-anal-
yses is that they allow subgroup analyses to be performed.
For both main endpoints, subgroup analyses will be
undertaken to determine if the effect of iNO treatment
differs depending on patient-level characteristics. That is,
are there any particular patient characteristics that deter-
mine who may benefit from inhaled Nitric Oxide. These
analyses will allow us to take into account each individual
infant's own characteristics rather than relying on sum-
mary measures of the average risk profile of all patients in
an individual trial. We will examine the following charac-
teristics:
1. Gestational age at birth
2. Birth weight
Subhedar 
1997
42 preterm infants, < 32 wks, assessed at 
96 hrs age for: mechanical ventilation 
since birth, had received surfactant, and 
high risk of developing CLD using a 
modified prediction score
Inhaled Nitric Oxide at 20 ppm for 2 hrs then 
weaned according to response criteria (positive 
response: decrease in OI by >=25% or reduction in 
FiO2 of >=0.10) by 5 ppm increments every 15 
mins until 5 ppm level for further 72 hrs, then 
weaned off; 2 × 2 factorial trial of iNO vs control 
and IV dexamethasone vs control
Death before discharge or CLD 
(oxygen dependency for at least 
28 days and beyond 36 wks pma 
with abnormal CXR)
Van Meurs 
2005
420 preterm infants, < 34 weeks, 401-
1500 g birthweight, assisted ventilation, 
OI >=10 on two consecutive blood 
gases 30 min -12 hrs apart at least 4 hrs 
after surfactant
Inhaled Nitric Oxide initially at 5-10 ppm; weaning 
commenced 10-14 hrs after initiation according 
to response criteria (change in PaO2); at 30 min 
intervals; maximum duration was 336 hours
Death or BPD at 36 wks in 
survivors
EUNO 2008 800 preterm infants <29 wks, 
birthweight >=500 g requiring either 
surfactant or CPAP >4 cmH2O with FiO2 
>0.3 to maintain SpO2 ≥ 85%
Inhaled NO 5 ppm for minimum 7 to maximum of 
21 days if still requiring respiratory support 
(including CPAP use)
Survival without BPD at 36 wks 
post conceptional age
a/A: arterial/alveolar oxygen ratio
BPD: bronchopulmonary dysplasia
CLD: chronic lung disease
CMV: continuous mechanical ventilation
CPAP: continuous positive airway pressure
CXR: chest X ray
FiO2: fraction of inspired oxygen
g: grams
HFOV: high-frequency oscillatory ventilation
hrs: hours
iNO: inhaled Nitric Oxide
OI: oxygenation index
pma: postmenstrual age
ppm: parts per million
RDS: respiratory distress syndrome
SpO2: oxygen saturation
wks: weeks
Table 2: MAPPiNO Collaboration: description of eligible trials as at October 2009 (Continued)
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Page 8 of 103. Postnatal age at entry into the study
4. Severity of lung disease (at study entry)
5. Inhaled Nitric Oxide dosage
6. Duration of therapy
7. Measure of iNO exposure (incorporating dose and
duration)
8. Antenatal steroid administration
9. Postnatal steroids administration before initiation
of iNO
10. Ventilation mode at randomization
11. Administration of exogenous surfactant
12. Presence of pulmonary hypertension
13. Multiple birth
14. Race
Planned sensitivity analyses
The following sensitivity analyses will be performed for
the main outcomes to compare the overall estimates of
treatment effect calculated on all data, to estimates based
on subsets of the data with the following data removed:
• Trials with <50 study patients
• Trials with inadequate concealment of allocation or
blinding
• Trials with high rates of patient exclusions (>40%)
Planned additional analyses
Multivariable regression models will be developed to
determine which patient-level characteristics are predic-
tive of the main outcomes.
Ethical considerations
Participants in the individual trials have previously given
informed consent to participate in their respective trial.
The data for this project are to be used for the purpose
for which they were originally collected and are available
through an agreement between all trialists of the collab-
orative group. These trialists remain the custodian of
their original individual trial data at all times.
Project management
Membership of the MAPPiNO Collaboration will include
representative(s) from each of the trials contributing data
to the review with an accompanying project coordination
and data management structure as described in this sec-
tion.
The membership and responsibilities of each of these
management groups are as follows:
Steering Group
The Steering Group will be responsible for project man-
agement decisions and will meet approximately 4-6 times
per year, usually via teleconference. Membership: N
Finer1 (chair), K Barrington2, R Ehrenkranz3, W Rich1, L
Askie4 (data coordination manager), A Carberry4(data
manager).
1 Division of Neonatology, University of California, San
Diego, USA;
2 Division of Neonatology, Centre Hospitalier Universi-
taire Ste-Justine, Montreal;
3 Department of Paediatrics, Yale University School of
Medicine, USA;
4 NHMRC Clinical Trials Centre, University of Sydney,
Australia.
Advisory Group
The aim of the Advisory Group is to facilitate representa-
tive input from the Collaborative Group to the Steering
Group if this is warranted. Membership of the Advisory
Group will be at the invitation of the Steering Group.
Collaborative Group
All potentially eligible trialists will be contacted and
invited to become members of the Collaborative Group.
The corresponding author for each study will be con-
tacted in the first instance. If there is no response, the
associated statistician, data manager and/or other
authors will be contacted. This process will be updated
annually for the duration of the project, to ensure that
new trialists are offered the opportunity to join the proj-
ect and contribute their data.
Data Coordination Centre
The project will be coordinated from the NHMRC Clini-
cal Trial Centre, University of Sydney, NSW, Australia.
The Data Coordination Centre will be responsible for the
daily management of the project including correspon-
dence, newsletter production, maintaining current trialist
contact information, meeting and teleconference organi-
sation, and receipt, storage and analysis of project data as
directed by the Collaborative Group via the Steering
Group.
Collaborators' meetings
All members of the Collaboration, including the Steering
Group, the Advisory Group, and representatives of each
participating trial, will be invited to attend regular collab-
orators' meetings. The meetings will be designed to allow
maximum input from the participating trialists into the
design, conduct, analysis and reporting of the project's
results.
Publication policy
The results of the project's analyses will be presented to,
and discussed with, the Collaborative Group before pre-
sentation and publication. The main manuscript will be
prepared by the Steering Group, and circulated to the
Collaborative Group for comment and revision. The
revised draft paper then will be circulated to all members
of the Collaborative Group for comment and agreement
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Page 9 of 10before publication. Publications using these data will be
authored on behalf of the Meta Analysis of Preterm
Patients on inhaled Nitric Oxide (MAPPiNO) Collabora-
tion, either with specific named authors, or on behalf of
the Collaboration as a whole. Names of other participat-
ing Collaborators will be acknowledged in an appropriate
section of the manuscript.
Discussion
A recently updated meta-analysis [27] showed that
inhaled Nitric Oxide marginally reduced the incidence of
death or CLD as well as severe brain damage in two stud-
ies where iNO was used routinely for mildly sick preterm
infants. However, uncertainty remains as a larger study
(Kinsella 2006) showed no significant benefit for iNO.
Trials including very ill infants or with later iNO treat-
ment using standard meta-analytic techniques did not
demonstrate a significant effect of iNO. Using techniques
to correct for the possible confounding effects of having
infants from multiple gestations enrolled in the same
group (multiple outputation and general estimating equa-
tions) one trial (Ballard 2006) did show a significant
reduction in the combined outcome of death or CLD
with treatment which commenced between 7 and 21
days. The best way to answer these remaining questions
is to utilize existing individual patient data from all
infants enrolled in these trials. This approach has been
described as the 'gold standard' of systematic review
methodology as it allows for more powerful and flexible
analysis of both subgroups and outcomes. The MAP-
PiNO Collaboration has been formed to undertake a sys-
tematic review of all available trials, with meta-analysis
based on individual patient data, to answer these impor-
tant clinical questions. Provision of data by the partici-
pating Collaborators commenced in 2007 and results will
be ready for presentation in 2010.
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